MedTrace Logo

Risk Factors for Progressive Supranuclear Palsy (PSP)

NCT00431301 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 942

Last updated 2017-04-10

No results posted yet for this study

Summary

Progressive supranuclear palsy (PSP) is the most common atypical parkinsonian movement disorder. This study will determine the role of specific genetic, occupational and environmental components in the development of PSP by evaluating patients with this disorder and age and gender matched controls.

Conditions

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • University of Louisville

    lead OTHER

Principal Investigators

  • Irene Litvan, M.D. · University of Louisville

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-08-31
Primary Completion
2013-02-28
Completion
2013-06-30

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00431301 on ClinicalTrials.gov